Home » Resources / Publications & Posters / Poster: Preclinical Epilepsy - the GAERS Model
The aim of this study was to assess the antiepileptic effect of PF-06372865, a newly-developed subtype-selective GABAA positive allosteric modulator, from Pfizer, in a preclinical model of absence seizures, the GAERS rat. PF-06372865 dose-dependently reduced spike wave discharges on EEG traces in the GAERS model. The pharmacology of the GAERS model has been shown to translate to the clinic: For instance, valproate, ethosuximide and levetiracetam show an anti-epileptic effect in this model and in humans. PF-06372865 is structurally different to other benzodiazepines and has a better affinity for the GABAA receptor with less adverse effect.